Revenue
No reported data
Eikon Therapeutics, Inc. (EIKN)
Price—Loading quote
Net income
2023
2024
Free cash flow
2023
2024
Total cash / debt
CashTotal debt
2023
2024
Financial statements
| 2024 | 2023 | |
|---|---|---|
| Research & development | $204.5M | $207.3M |
| Operating income | −$260.3M | −$265.7M |
| EBITDAderived | −$245.3M | −$254.3M |
| Net income | −$243.8M | −$242.0M |
| Diluted EPSper diluted share | -$96.76 | -$119.40 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 6, 2026Form 4 | Column Group Opportunity III, LP +7TenPercentOwner | BuyCommon Stock · indirect | 630.9K | $18.00 | $11.36M | 1.32M |
| Feb 6, 2026Form 4 | Column Group Opportunity III, LP +7TenPercentOwner | BuyCommon Stock · indirect | 49.6K | $18.00 | $892.0K | 148.8K |
| Feb 6, 2026Form 4 | Column Group Opportunity III, LP +7TenPercentOwner | BuyCommon Stock · indirect | 1.44M | $18.00 | $25.87M | 4.31M |
| Feb 4, 2026Form 4 | FRAZIER KENNETH CDirector | BuyCommon Stock | 111.1K | $18.00 | $2.00M | 111.1K |
| Feb 4, 2026Form 4 | Wolfe JoshDirector,TenPercentOwner | BuyCommon Stock · indirect | 138.9K | $18.00 | $2.50M | 138.9K |